|
在研的主要项目
1）国家自然科学基金面上项目，阳离子四价铂与p53 mRNA共载高分子纳米药物协同增强高级别浆液性卵巢癌免疫治疗，2024/01-2027/12，在研；
2）含铂/硼高分子纳米药物的构建及其在化疗协同硼中子治疗（BNCT）中的应用和机制研究，主持，广东省基础与应用基础研究基金 区域联合基金项目（重点项目），2023-11-01-2026-10-31，在研；
3）广东省自然科学基金，阳离子前药高分子递送mRNA用于治疗高级别浆液性卵巢癌的研究，2024/01-2026/12，在研；
4）南方医科大学附属第十医院高层次人才引进科研项目，铂药给药系统的构建及其抗癌作用机制的研究， 2022/05-2026/04，在研。
发表的代表性论文
1. Guimei Chen, et. al., Zhiqiang Yu*. Carrier-Free Photodynamic Bioregulators Inhibiting Lactic Acid Efflux Combined with Immune Checkpoint Blockade for TripleNegative Breast Cancer Immunotherapy, ACS Nano 2024, 18, 19875−19889. (IF:18.03，中科院1区)
2. Wenjia Zhang. et. al.,Zhiqiang Yu*.Mitochondria-targeted polyprodrug nanoparticles induce mitochondrial stress for immunogenic chemo-photodynamic therapy of ovarian cancer, Journal of Controlled Release 371 (2024) 470–483. (IF:11.47，中科院1区，药剂学TOP期刊);
3. Ma W, Sun R, Tang L, Z Li, L Lin, Z Mai, G Chen, Z Yu*. Bioactivable STING nanoagonists to synergize Nir-Ii mild photothermal therapy primed robust and long-term anticancer immunity (published online ahead of print). Adv Mater. 2023; e2303149. (IF:27.4，中科院1区)
4. Zhang B, Wang Y, Wang S, Tang Y, Li Z, Lin L, Wu Y*, Yu Z*. Precise RNA editing: cascade self-uncloaking dual-prodrug nanoassemblies based on CRISPR/Cas13a for pleiotropic immunotherapy of PD-L1-resistant colorectal cancer. Advanced Functional Materials, 2023: 2305630. (IF:19，中科院1区)
5. Yuanyuan Yang, Ziyi Mai, Yanxin Zhang, Zhiyu Yu, Wenjing Li, Yuxuan Zhang, Fangzhou Li, Peter Timashev, Ping Luan, Dixian Luo, Xing-jie Liang, Zhiqiang Yu*. A cascade targeted and mitochondrion-dysfunctional nanomedicine capable of overcoming drug resistance in hepatocellular carcinoma, ACS Nano, 2023, 17 (2), 1275-1286. (IF:18.03，中科院1区)
6. Ziyi Mai, Jing Zhong, Jiasi zhang, Guimei Chen, Yan Tang, Wen Ma, Guang Li, Zhenzhen Feng, Fangzhou Li, Xin-jie Liang, Yuanyuan Yang*, Zhiqiang Yu*. Carrier-Free Immunotherapeutic Nano- Booster with Dual Synergistic Effects Based on Glutaminase Inhibition Combined with Photodynamic Therapy, ACS Nano, 2023, 17, 2, 1583–1596. (IF:18.03，中科院1区)
7. Wang, Zhenjie, Yu, Ling, Wang, Yuehua, et al., Yu Zhiqiang*. Dynamic Adjust of Non-Radiative and Radiative Attenuation of AIE Molecules Reinforces NIR-II Imaging Mediated Photothermal Therapy and Immunotherapy. Adv Sci. 2022;9(8). (IF:17.52，中科院1区，生物材料TOP期刊;
8. Gong, Wanjun, Jiang, Lingdong, Zhu, Yanxia, Yu Zhiqiang*, et al. An Activity-Based Ratiometric Fluorescent Probe for In Vivo Real-Time Imaging of Hydrogen Molecules. Angew Chem Int Edit. 2022;61(9). (IF:16.82，中科院1区);
9. Wang, Yuehua, Wang, Zhenjie, Jia, Fei, et al., Yu Zhiqiang*.. CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment. Bioactive Materials, 2022(17), 147-161. (IF:16.87，中科院1区，生物材料TOP期刊);
10. Chen, Gui, Xu, Qing, Feng, Zhenzhen, et. al., Yu Zhiqiang*, Meng Yu*, Glutamine antagonist synergizes with electrodynamic therapy to induce tumor regression and systemic antitumor immunity, ACS Nano, 2022, 16, 1, 951–962. (IF:18.03，中科院1区);
11. Xu, Qing, Chen, Gui, Chen, Guimei, et al., Yu Zhiqiang*. NO-dependent vasodilation and deep tumor penetration for cascade-amplified antitumor performance. J Control Release. 2022;347:389-99. (IF:11.47，中科院1区，药剂学TOP期刊);
12. Yang, Yuanyuan, Liu, Xin, Ma, Wen, et al., Yu Zhiqiang*. Light-activatable liposomes for repetitive on-demand drug release and immunopotentiation in hypoxic tumor therapy. Biomaterials. 2021;265. (IF:15.304，中科院1区).
|